QBiotics 2025 AGM Chair key remarks
BRISBANE, November 21, 2025
Ahead of the coming QBiotics Group Limited (QBiotics) Annual General Meeting (AGM) on Tuesday November 25, 2025, a copy of Non-Executive Chairman, Mr Mark Fladrich’s key remarks are being provided in the link below to support shareholders with clear, factual information when considering this year’s resolutions. Release of the Chair key remarks ahead of time reflects the Company’s commitment to transparency and good governance. We look forward to welcoming shareholders to the meeting.
QBiotics 2025 AGM Chair key remarks
—ends—
FURTHER INFORMATION
STEPHEN DOYLE, CEO & MANAGING DIRECTOR
communications@qbiotics.com
or
MEDIA ENQUIRIES
KIRSTEN BRUCE, PRINCIPAL, VIVA! COMMUNICATIONS
kirstenbruce@vivacommunications.com.au or +61 401 717 566
NOTES FOR EDITORS
ABOUT QBIOTICS
QBiotics is an unlisted, public, Australian life sciences company that seamlessly connects scientific discovery, development and commercialisation to harness the power of nature to treat diseases of high unmet need.
Our current clinical focus is on novel treatments for cancer and debilitating chronic wounds. We also have an early-stage antibiotics program.
QBiotics’ lead molecule, tigilanol tiglate, is a novel, small molecule with the potential to treat a broad range of solid tumours. It is currently in Phase II clinical trials in two indications: soft tissue sarcoma (STS) and head and neck cancer (HNC). Tigilanol tiglate was granted Orphan Drug Designation by the US FDA for the treatment of STS in February 2024.
A veterinary formulation of tigilanol tiglate (STELFONTA®) is approved for the treatment of canine mast cell tumours (MCTs), in major global markets, including the USA, Europe, and Australia. QBiotics has partnered with Virbac, a global animal health company, to distribute STELFONTA®.
Our wound healing drug candidate, EBC-1013, is a small molecule, which targets multiple pathways to accelerate healing, improving outcomes in chronic and acute wounds and burns. A first-in-human Phase I clinical trial in venous leg ulcers is open for recruitment.
For more, head to: QBiotics.com or LinkedIn